Shares of Nyxoah tumbled sharply in mid-day trading, dropping roughly 47.9% after the Belgium-based medical technology firm disclosed the terms of a significant equity offering. The company set the price for an underwritten public offering at $1.72 per ordinary share, intending to raise approximately $95 million by issuing in excess of 55 million new shares.
The size of the offering raised immediate concerns about dilution among existing shareholders. Nyxoah noted that underwriters hold an overallotment option for an additional 8.28 million shares. If that option is exercised in full, the transaction could push the company's outstanding share count materially higher - potentially increasing the share base by well over 100% relative to the current level - a prospect that spurred heavy selling pressure.
The equity raise followed a separate disclosure the previous day that the company has launched a formal search for a U.S.-based chief executive officer. Current CEO Olivier Taelman will remain in a transitional capacity while the search is underway. In the same update, Nyxoah said its existing cash resources are projected to last only through the third quarter of 2026, underscoring the urgency behind the capital infusion.
Market reaction was compounded by company-specific operational and legal developments. Nyxoah indicated that its long-running collaboration with Cochlear Limited has effectively ended. At the same time, the company is engaged in an escalating patent dispute with rival Inspire Medical Systems in both U.S. and European courts. Those disputes introduce additional financial and operational uncertainty for the business.
Broader market dynamics provided little support for the embattled stock. During the session, the NASDAQ fell 3.0%, the S&P 500 declined 1.9%, and the Dow Jones Industrial Average dropped 0.8%. That risk-off move across equities exacerbated selling in smaller, pre-profitability medical device names, including Nyxoah.
Intraday trading also pushed Nyxoah to a fresh 52-week low of $1.44, highlighting the stretch between the recent low and the company's 52-week high of $8.59. Mid-day quotes showed the stock trading around $1.50 as investors reacted to the combination of the dilutive financing, leadership transition, constrained cash runway, unresolved patent litigation, and an unfavorable market backdrop.
Key takeaways:
- Nyxoah priced a $95 million underwritten public offering at $1.72 per share for more than 55 million new ordinary shares, with an additional 8.28 million-share overallotment option.
- The company announced a search for a U.S.-based CEO while current CEO Olivier Taelman remains in a transitional role and disclosed a cash runway into the third quarter of 2026.
- Nyxoah faces heightened uncertainty after the effective end of its collaboration with Cochlear and an escalating patent dispute with Inspire Medical Systems in U.S. and European courts.
Contextual note: The combination of a deeply dilutive capital raise, leadership transition, constrained liquidity horizon, active litigation and a weak equity market produced the rapid sell-off in Nyxoah shares observed during the trading session.